Table 1. Patients characteristics (N = 4).
| Patient Identifier | ||||
| 3180 | 3242 | 3501 | 3508 | |
| Baseline CD4 count (cells/mm3) | 5 | 331 | 3 | 3 |
| Baseline log viral load (log10 copies/mL) | 6.09 | 4.07 | 5.27 | 4.63 |
| Number of days on raltegravir | 177 | 224 | 338 | 412 |
| Number of days monitored post-baseline | 462 | 497 | 338 | 412 |
| First raltegravir-containing regimen | ABC,3TC,ETV,RGV | FTC/TDF,RTV,DRV,MVR,RGV | TDF,ABC/3TC,RTV,TPV,RGV | FTC/TDF,RTV,DRV,MVR,HGH,RGV |
| Age at baseline | 52 | 48 | 47 | 46 |
| Gender | Male | Male | Male | Male |
| Ethnicity | Black/African American | White/European American | Black/African American | White/European American |
| HIV-1 subtype | B | B | B | B |
| Raltegravir resistance pathway(s) post-therapy in plasma and PBMC | Q148H | N155H | Q148H | Y143H/C/R, Q148R, N155H |
“Baseline” is defined as the initiation of a raltegravir-containing regimen. ABC (abacavir), 3TC (lamivudine), ETV (etravirine), RGV (raltegravir), FTC (emtricitabine), TDF (tenofovir), RTV (ritonavir), DRV (darunavir), MVR (maraviroc), TPV (tipranavir), HGH (human growth hormone).